Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer
NL-OMON45803Phase 2Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), prostate adenocarcinoma and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Radboud University Medical Center. Primary endpoint: PSA response. Planned start Oct 2018; status: withdrawn.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)prostate adenocarcinomametastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON45803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45803.